AML Therapies: Seattle Genetics Vs. GlycoMimetics

Jul. 15, 2016 8:10 AM ETGlycoMimetics, Inc. (GLYC), SGENJUNO6 Comments
William Meyers profile picture
William Meyers


  • Acute Myeloid Leukemia is very difficult to treat successfully.
  • Seattle Genetics SGN-CD33A started a Phase 3 trial.
  • GlycoMimetics GMI-1271 started Phase 2 trial.
  • There are other competitors, but it is unlikely AML will be 100% cured by any one therapy.

AML (Acute Myeloid Leukemia) is a deadly disease of the blood system. In the main, it is still treated with decades-old chemotherapies. Several promising therapies have failed during clinical trials in the last decade. Any therapy that does succeed in getting an FDA approval for use will likely generate hundreds of millions in annual revenue.

Seattle Genetics (NASDAQ:SGEN) is a commercial stage biotechnology pharmaceutical company with an extensive pipeline of clinical stage drugs targeting a variety of diseases. It had revenue of $111 million in Q1 and a GAAP net loss of $20.5 million. Its sole commercial product so far is Adcetris for CD30-positive Hodgkin's Lymphoma and ALCL. Its potential AML therapy is SGN-CD33A. For its broader pipeline see Seattle Genetics: The Long View. Seattle Genetics is a mid-cap company with a current market capitalization of about $6 billion.

GlycoMimetics (NASDAQ:GLYC) is a developmental stage company with two therapies in the clinic. The more advanced therapy is Rivipansel for Vaso-occlusive crisis, which is partnered with Pfizer (PFE) and started a Phase 3 trial in June 2015. For more background, see GlycoMimetics: Undercovered with Catalysts Coming. Its AML therapy is GMI-1271, which reported positive results from a Phase 1 trial in May, and started its Phase 2 trial in late June. GlycoMimetics is a micro cap with a market capitalization of $138 million.

Juno Therapeutics (JUNO) also has a proposed AML therapy, JTCR016, which is in a Phase 1 trial. Given the recent problems with Juno's JCAR015 trial for ALL (acute lymphoblastic leukemia), and that only preliminary data is available for JTCR016, I will not treat it in depth in this article. I am mentioning it simply as one example of other approaches to treating AML that are in development or contemplated. Juno is a mid-cap company with a market cap of $3 billion, but that has been very volatile

This article was written by

William Meyers profile picture
I provided stock and bond research and analysis to a small cap specialist investor, Lloyd Miller, from 2002 until his death in January 2018. For my own account I invest mainly in technology and biotechnology stocks. My technology and investment web site is, where readers can view the notes I take to make decisions and to write articles for Seeking Alpha.

Disclosure: I am/we are long GLYC, SGEN, JUNO. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You

Comments (6)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.